title: Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic.
abstract: OBJECTIVE
  To determine the extent of and clinical variables associated with zidovudine compliance.
  
  
  METHODS
  A survey of 83 patients infected with human immunodeficiency virus (HIV) followed in a municipal hospital clinic was performed. Compliance histories were validated by serum and urine zidovudine levels. Patient characteristics included 46% white, 63% with a history of intravenous drug use, and 59% reporting a diagnosis of acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). The main outcome measure was greater than 80% compliance with prescribed doses of zidovudine over the previous week.
  
  
  RESULTS
  Sixty-seven percent of the study patients reported greater than 80% compliance with prescribed doses of zidovudine over the previous week. The most common explanations given for missing a dose were "forgot to take zidovudine" and "did not have the medication with me." Five variables were independently associated with greater than 80% compliance as determined by stepwise multiple logistic regression: patient belief that zidovudine prolongs life (odds ratio [OR] 9.3, [95% confidence interval (CI) 2.4, 36.7]), a diagnosis of AIDS or ARC (OR 5.5, [CI 1.5, 20.4]), use of a medication timer (OR 4.4, [CI 1.0, 19.1]), no history of intravenous drug use (OR 3.7, [CI 1.0, 14.2]), and taking one to three other medications with zidovudine.
  
  
  CONCLUSIONS
  High compliance with zidovudine was achieved by HIV-infected patients in a municipal hospital clinic, many of whom had a history of intravenous drug use. Compliance with zidovudine may be enhanced by a patient's belief that it prolongs life and the use of a medication timer for proper dosing.
authors.affiliation: Department of Medicine, Boston University School of Medicine, Massachusetts.
authors.forename: J H
authors.initials: JH
authors.lastname: Samet
authors.forename: H
authors.initials: H
authors.lastname: Libman
authors.forename: K A
authors.initials: KA
authors.lastname: Steger
authors.forename: R K
authors.initials: RK
authors.lastname: Dhawan
authors.forename: J
authors.initials: J
authors.lastname: Chen
authors.forename: A H
authors.initials: AH
authors.lastname: Shevitz
authors.forename: R
authors.initials: R
authors.lastname: Dewees-Dunk
authors.forename: S
authors.initials: S
authors.lastname: Levenson
authors.forename: D
authors.initials: D
authors.lastname: Kufe
authors.forename: D E
authors.initials: DE
authors.lastname: Craven
mesh_terms: D000386:AIDS-Related Complex / Q000188:drug therapy / Q000523:psychology; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000523:psychology; D000328:Adult; D001294:Attitude to Health; D001900:Boston; D003430:Cross-Sectional Studies; D005260:Female; D015497:HIV-1; D006773:Hospitals, Municipal; D006801:Humans; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital; D010349:Patient Compliance; D015819:Substance Abuse, Intravenous / Q000150:complications; D015215:Zidovudine / Q000097:blood / Q000627:therapeutic use* / Q000652:urine
chemical_list: D015215:Zidovudine